RARE

+ Watchlist + Portfolio

Ultragenyx Pharmaceutical Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.24
52-Week Range: $18.29 – $39.89
Market Cap: $2.50B
P/E (TTM): —
EPS (TTM): -5.83
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -24.22%
Gross Margin: -20.78%
Operating Margin: -35.05%
Profit Margin: -81.73%
Current Ratio: 1.73
Debt/Equity: —
Total Debt: $1.20B
Free Cash Flow: $-179.83M
Revenue Growth: 28.10%
Earnings Growth: —
Enterprise Value: $3.50B

RARE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$363.33M	$434.00M	$560.00M	$673.00M
Cost of Revenue	$28.32M	$45.00M	$77.00M	$109.00M
Gross Profit	$335.01M	$389.00M	$483.00M	$564.00M
Research & Development	$705.79M	$648.00M	$698.00M	$750.00M
Selling, General & Admin	$278.14M	$310.00M	$321.00M	$349.00M
Operating Expenses	$983.93M	$958.00M	$1.02B	$1.10B
Operating Income	-$648.92M	-$569.00M	-$536.00M	-$535.00M
EBITDA	-$640.49M	-$517.00M	-$468.00M	-$474.00M
Pretax Income	-$701.73M	-$609.00M	-$567.00M	-$571.00M
Income Tax	$5.70M	-$2.00M	$2.00M	$4.00M
Net Income	-$707.42M	-$607.00M	-$569.00M	-$575.00M
Diluted EPS	-10.12	-8.25	-6.29	-5.83
Diluted Shares	69.91M	73.54M	90.54M	98.60M

RARE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$132.94M	$213.58M	$174.00M	$421.00M
Receivables	$40.45M	$73.39M	$122.00M	$158.00M
Inventory	$26.77M	$33.97M	$45.00M	$52.00M
Current Assets	$883.90M	$732.18M	$817.00M	$951.00M
Total Assets	$1.55B	$1.49B	$1.50B	$1.53B
Current Liabilities	$261.21M	$280.44M	$344.00M	$384.00M
Total Debt	$31.59M	$43.17M	$40.00M	$36.00M
Total Liabilities	$1.19B	$1.22B	$1.24B	$1.60B
Retained Earnings	-$2.78B	-$3.39B	-$3.96B	-$4.53B
Shareholders' Equity	$352.49M	$275.41M	$255.00M	-$80.00M
Working Capital	$622.69M	$451.75M	$473.00M	$567.00M

RARE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$380.46M	-$475.00M	-$414.00M	-$466.00M
Capital Expenditure	-$146.12M	-$47.00M	-$20.00M	-$21.00M
Free Cash Flow	-$526.59M	-$522.00M	-$434.00M	-$487.00M
Depreciation & Amortisation	$18.22M	$26.00M	$36.00M	$35.00M
Stock-Based Compensation	$130.38M	$135.00M	$158.00M	$153.00M
Investing Cash Flow	-$291.65M	$168.00M	-$18.00M	$236.00M
Financing Cash Flow	$501.21M	$388.00M	$399.00M	$478.00M
Net Change in Cash	-$170.91M	$81.00M	-$33.00M	$248.00M

RARE Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$167.00M	$159.93M	$207.28M	$136.00M	$214.00M
Cost of Revenue	$23.00M	$27.99M	$29.34M	$30.00M	$34.00M
Gross Profit	$144.00M	$131.94M	$177.93M	$106.00M	$180.00M
Research & Development	$165.00M	$216.21M	$203.28M	$187.00M	$167.00M
Selling, General & Admin	$87.00M	$86.62M	$87.94M	$88.00M	$88.00M
Operating Expenses	$252.00M	$302.83M	$291.22M	$275.00M	$255.00M
Operating Income	-$108.00M	-$170.89M	-$113.28M	-$169.00M	-$75.00M
EBITDA	-$91.00M	-$157.18M	-$99.43M	-$155.00M	-$61.00M
Pretax Income	-$114.00M	-$179.54M	-$127.69M	-$184.00M	-$91.00M
Income Tax	$1.00M	$873.00K	$870.00K	$1.00M	$1.00M
Net Income	-$115.00M	-$180.41M	-$128.56M	-$185.00M	-$92.00M
Diluted EPS	-1.17	-1.81	-1.29	-1.84	-0.90
Diluted Shares	98.50M	99.77M	99.90M	100.60M	101.90M

RARE Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$166.11M	$202.51M	$421.00M	$175.00M	$125.00M
Receivables	$124.46M	$112.54M	$158.00M	$121.00M	$200.00M
Inventory	$46.50M	$52.20M	$52.00M	$55.00M	$59.00M
Current Assets	$719.79M	$643.21M	$951.00M	$657.00M	$606.00M
Total Assets	$1.31B	$1.19B	$1.53B	$1.30B	$1.26B
Current Liabilities	$293.24M	$340.02M	$384.00M	$325.00M	$351.00M
Total Debt	$36.30M	$33.83M	$36.00M	—	—
Total Liabilities	$1.15B	$1.17B	$1.60B	$1.52B	$1.55B
Retained Earnings	-$4.22B	-$4.40B	-$4.53B	-$4.72B	-$4.81B
Shareholders' Equity	$151.29M	$9.16M	-$80.00M	-$236.00M	-$291.00M
Working Capital	$426.54M	$303.18M	$567.00M	$332.00M	$255.00M

RARE Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$109.00M	-$91.17M	-$99.83M	-$197.00M	-$97.00M
Capital Expenditure	-$3.00M	-$1.06M	-$938.00K	-$6.00M	-$1.00M
Free Cash Flow	-$112.00M	-$92.23M	-$100.77M	-$203.00M	-$98.00M
Depreciation & Amortisation	$9.00M	$8.21M	$8.79M	$8.00M	$8.00M
Stock-Based Compensation	$38.00M	$37.71M	$37.29M	$30.00M	$34.00M
Investing Cash Flow	$71.00M	$117.25M	-$72.25M	-$49.00M	$44.00M
Financing Cash Flow	$83.65M	-$192.00K	$394.19M	—	—
Net Change in Cash	$46.12M	$25.76M	$222.12M	-$246.00M	-$50.00M

Market Snapshot

About

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases, with approved treatments for metabolic and bone disorders.